DDInter576 DDInter905
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Disulfiram {u} (Compound) treats {v} (Disease) alcohol dependence
alcohol dependence {u} (Disease) is treated by {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Disulfiram {u} (Compound) binds {v} (Gene) DBH
DBH {u} (Gene) is bound by {v} (Compound) Propylthiouracil
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Disulfiram {u} (Compound) treats {v} (Disease) alcohol dependence
alcohol dependence {u} (Disease) is treated by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Disulfiram {u} (Compound) upregulates {v} (Gene) IL11
IL11 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKB2
NFKB2 {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Disulfiram {u} (Compound) upregulates {v} (Gene) CTSL
CTSL {u} (Gene) is bound by {v} (Compound) Boceprevir
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Disulfiram (Compound) treats alcohol dependence (Disease) and alcohol dependence (Disease) is treated by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Disulfiram (Compound) binds DBH (Gene) and DBH (Gene) is bound by Propylthiouracil (Compound) and Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Disulfiram (Compound) treats alcohol dependence (Disease) and alcohol dependence (Disease) is treated by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Idelalisib
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Idelalisib
Disulfiram (Compound) upregulates IL11 (Gene) and IL11 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Disulfiram (Compound) upregulates NFKB2 (Gene) and NFKB2 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Disulfiram (Compound) upregulates CTSL (Gene) and CTSL (Gene) is bound by Boceprevir (Compound) and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib